Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
COVID-19 response coordinator says adults older than 60 should get second booster
Apr 18, 2022
The FDA authorized a second booster of the Pfizer and Moderna vaccines on March 29 for anyone 50 years and older.
Third mRNA COVID-19 vaccine dose appears to be safe
Apr 15, 2022
There were higher reports of low-severity adverse effects but no change in severe events.
Vaccination offers extra protection after SARS-CoV-2 infection
Apr 06, 2022
Two studies show additional protection against reinfection and COVID-19-linked hospitalization with vaccination.
FDA panel meets to craft future vaccine strategy
Apr 06, 2022
No official vote is planned, and no specific vaccine products will be discussed.
Risk for acute MI not increased with two-dose HepB-CpG vaccine
Apr 01, 2022
The noninferiority study shows no increased risk for acute myocardial infarction with the two-dose HepB-CpG vaccine versus the three-dose HepB-alum vaccine.
Booster strategies after Janssen shot increased protection against omicron
Mar 30, 2022
Vaccination with one Janssen dose plus mRNA booster provides higher protection than two Janssen doses.
Risk for myocarditis low after third dose of BNT162b2 vaccine
Mar 24, 2022
The incidence of myocarditis among young men estimated to be 6.43 and 11.25 per 100,000 vaccines in the week to two weeks after third dose..
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.